Abstract Objectives In Europe, most people with HIV‐1(PWH) achieve virologic suppression with effective and well‐tolerated antiretroviral therapies (ART). In this context, patient‐reported outcomes (PRO) are increasingly important for evaluating ART benefits. This study aimed to describe treatment durability, satisfaction and quality of life (QoL) in virologically suppressed PWH switching to a doravirine‐based regimen (PWH‐DOR). Methods DoraVIH was a national, multicentre, real‐world cohort study with two phases: cross‐sectional and prospective follow‐up of PWH‐DOR at 3 (M3) and 15–18 months (M15–18) post‐switch. Durability of the doravirine‐based regimen was recorded at both follow‐up visits, and on‐treatment virologic response at M3. QoL was assessed at baseline (D0) and M15–18 using the SF‐36 questionnaire. Pre‐switch patient satisfaction with treatment was assessed at D0 using the HIV Treatment Satisfaction Questionnaire (HIVTSQs), and post‐switch at M3 and M15–18 using the HIVTSQc. Results Among 143 PWH‐DOR included (mean age 51.1 ± 10.6 years; 68% men), durability was 94% (131/140) at M3 and 83% (114/138) at M15–18. All participants receiving doravirine at M3 remained virologically suppressed. SF‐36 scores showed no significant QoL change between D0 (72.6 ± 17.2) and M15–18 (73.0 ± 19.6). Pre‐switch treatment satisfaction averaged 50.2 ± 9.6 (HIVTSQs score). Most PWH‐DOR reported better satisfaction (HIVTSQc score >0): 90% at M3 (96/107) and 90% at M15–18 (89/99). Conclusion Despite the absence of a control group and limited sample size, these real‐world data support the effectiveness of switching to a doravirine‐based regimen, with high durability and improved patient satisfaction.
Bruno et al. (2026) studied this question.